The effect of exogenous ovine prolactin (oPRL) on preovulatory follicle P450 17 alpha-hydroxylase (C17) and aromatase (ARO) mRNA abundance was investigated in turkeys. Ovine PRL (124 IU/hen per day) was injected i.m. into four sets (n = 8) of laying turkeys for 2, 4, 8, or 14 days. Vehicle was injected into control hens for 8 days (n = 8). Blood samples were collected and serum was assayed for LH, progesterone (P), testosterone (T), and estradiol (E). Theca layers from the largest (F1) and the third (F3), fifth (F5), and seventh (F7) largest preovulatory follicles and from small white follicles (SWF) were examined for C17 and ARO mRNA contents. The number of atretic follicles increased from 0 (vehicle-injected controls) to 9 (14-day-oPRL-injected hens). Serum E, T, and LH levels decreased, while P levels remained unchanged. There was a transient increase in theca C17 mRNA abundance of 2- and 4-day-oPRL-treated hen follicles. Cytochrome P450 ARO mRNA levels were reduced in SWF and F7 in response to oPRL. Thecal C17 and ARO mRNA content was reduced during follicular maturation in laying hens. ARO mRNA was not detectable in granulosa cells. The progressive decline in C17 and ARO mRNA content associated with follicular maturation as well as the absence of ARO mRNA in granulosa cells is consistent with the secretory activity of P, T, and E in preovulatory follicles. These findings suggest that reduced circulating E may be a consequence of suppressed ARO gene expression whereas the oPRL suppression of T secretion may not be coupled to C17 gene expression.

Download full-text PDF

Source
http://dx.doi.org/10.1095/biolreprod52.3.600DOI Listing

Publication Analysis

Top Keywords

aro mrna
28
c17 aro
12
cytochrome p450
8
p450 alpha-hydroxylase
8
aro
8
mrna
8
mrna abundance
8
preovulatory follicles
8
mrna content
8
follicular maturation
8

Similar Publications

LDL-C and TC mediate the risk of PNPLA3 inhibition on cardiovascular diseases.

J Clin Endocrinol Metab

April 2024

Department of Gastrointestinal Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.

Article Synopsis
  • PNPLA3 is a potential target for treating liver disease, and the drug ARO-PNPLA3 lowers its expression in liver cells, reducing fat, but long-term effects are unclear.
  • A study used genetic analysis to explore the link between PNPLA3 inhibition and cardiovascular diseases (CVDs), finding that certain genetic variants were associated with liver fat.
  • Results indicated that inhibiting PNPLA3 increased the risk of major CVDs like coronary heart disease and myocardial infarction, with blood cholesterol levels playing a significant role in these associations.*
View Article and Find Full Text PDF

Introduction: Being born either large (LGA) or small for gestational age (SGA) has been associated with an increased risk of developing metabolic syndrome in adulthood. However, the mechanism underlying this early programming remained unclear. Estrogen-related receptor gamma (ERRγ) is an orphan nuclear receptor with a high expression in human placenta, particularly ERRγ1.

View Article and Find Full Text PDF

Cymbopogon schoenanthus (L) extract ameliorates high fat diet-induced obesity and dyslipidemia via reducing expression of lipogenic and thermogenic proteins.

Fitoterapia

June 2024

Chemistry Department of Medicinal and Aromatic plants, Research Institute of Medicinal and Aro-matic plants (RIMAP), Beni-Suef University, Beni-Suef 62514, Egypt; China Light Industry Key Laboratory of Food Intelligent Detection & Processing, School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.

Globally, obesity has become one of the major health problems. This study was conducted to evaluate the anti-obesity potential of Cymbopogon schoenanthus methanolic extract (CS) in rats. Fifty male Wistar rats of six to eight weeks old, 100-120 g body weight (BW) were randomly assigned into 5 groups (n = 10): The control group was fed a basal diet.

View Article and Find Full Text PDF

Dyxin is a LIM-domain containing transcriptional regulator protein shown to play a role in a hypertrophic response in the heart. Here, the effect of adenoviral dyxin overexpression was studied on cardiac function and gene expression in the normal heart and in angiotensin II (Ang II)-induced hypertension in rats. The adenovirus-mediated intramyocardial gene transfer of dyxin (1.

View Article and Find Full Text PDF

Randomized Phase I Trials - One Size Fits All?

NEJM Evid

December 2023

Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, NY.

In this issue of , Gaudet et al. present the safety profile and pharmacodynamics of ARO-APOC3, a small interfering RNA therapeutic that inhibits apolipoprotein C-III (APOC3) mRNA expression in a phase I trial. Assignment to treatment was based on fasting levels of triglycerides.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!